Open AccessZanubrutinib (Brukinsa)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.253
Subject(s) - reimbursement , lymphoplasmacytic lymphoma , medicine , family medicine , waldenstrom macroglobulinemia , political science , lymphoma , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses zanubrutinib (Brukinsa), 80 mg oral capsules.Indication: Treatment of adult patients with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma).